The side-chain modification was performed using different modifiers under corresponding conditions (see Scheme 1 in the paper). For TA1: MPEG6-OH (0.2 mmol, 59 mg), HOBt (0.2 mmol, 27 mg), DIC (0.2 mmol, 25 mg), DMAP (0.1 mmol, 12 mg) were dissolved in DMF (4 mL). For TA2~TA6: R-H (0.2 mmol), HOBt (0.2 mmol, 27 mg), HBTU (0.2 mmol, 75 mg) and DIPEA (0.2 mmol, 26 mg) were dissolved in DMF (4 mL). For all reactions, the reaction mixture was shaken at room temperature for 24 hours. The solvent was filtered off and the resin was washed with DCM (3×5 mL) and DMF (3×5mL). R-H included MPEG6-NH2 (0.2 mmol, 57 mg), glucosamine hydrochloride (0.2mmol, 43 mg), 2-biotinamidoethylamine (0.2mmol, 65 mg), biotin hydrazide (0.2mmol, 52 mg) and dansylhydrazine (0.2mmol, 53 mg).
The resin was suspended in 20% piperidine in DMF (v/v, 5 mL) for 30 minutes. The solvent was filtered off and the resin was washed with DMF (3×5 mL). The resin was shrunk with MeOH (2×5 mL). The peptide was cleaved from the resin with 50% TFA in DCM (v/v, 5 mL) for 2 hours. The reaction mixture was filtered and the filtrate was concentrated under vacuum. The residue was dissolved in water, then freeze-dried to give the solid.
Synthesis of Arg-Lys(R')-Asp-Val-Tyr
Peptide was synthesized by SPPS using Fmoc/t-Bu strategy on 100 mg of Fmoc-Tyr(t-Bu)-Resin (0.05 mol, 0.52 mmol/g). The resin was suspended in 20% piperidine in DMF (v/v, 5 mL) for 30 minutes to remove the Fmoc group. The solvent was filtered off and the resin was washed with DMF (3×5 mL). For the attachment of the second amino acid, Fmoc-Val-OH (0.2 mmol, 68 mg) was anchored to the resin using EDC·HCl (0.2 mmol, 38 mg) and HOBt (0.2 mmol, 27 mg) in DMF (4 mL) for 2 hours, when a negative ninhydrin test was detected. After removal of the Fmoc group, attachment of Fmoc-Asp(OBu-t)-OH (0.2 mmol, 82 mg) to the resin and removal of the Fmoc group were performed using the same reaction conditions as Fmoc-Val-OH. Then, Fmoc-Lys(Mtt)-OH (0.2 mmol, 125 mg) was anchored to the resin using HOBt (0.2 mmol, 27 mg), HBTU (0.2 mmol, 75 mg) and DIPEA (0.2 mmol, 26 mg) in DMF (4 mL) for 4 hours, when a negative ninhydrin test was detected. After removal of the Fmoc group, attachment of Fmoc-Arg(Pbf)-OH (0.2 mmol, 130 mg) to the resin was performed using the same reaction conditions as Fmoc-Lys(Mtt)-OH.
The resin was treated with 5% TFA and 5% TIS in DCM (v/v, 5 mL, 2×5 minutes) to remove the Mtt group. A positive ninhydrin test (dark blue) indicated the reaction was complete. Then the resin was washed with DMF (3×5 mL), DCM (3×5 mL) and DMF (3×5 mL).
The side-chain modification was performed using different modifiers under corresponding conditions (see Scheme 1 in the paper). For TL1~TL2: R'-OH (0.2 mmol), HOBt (0.2 mmol, 27 mg), HBTU (0.2 mmol, 75 mg) and DIPEA (0.2 mmol, 26 mg) were dissolved in DMF (4 mL). The reaction mixture was shaken at room temperature for 4 hours. The solvent was filtered off and the resin was washed with DCM (3×5 mL) and DMF (3×5 mL). R'-OH included MPEG6-CH2-COOH (0.2 mmol, 71mg) and MPEG6-(CH2)5-COOH (0.2mmol, 82 mg). For TL3~TL6: R'-OSu (0.2 mmol) or FITC (0.2 mmol, 78 mg) was dissolved in DMF (4 mL), then DIPEA (0.2 mmol, 26 mg) was added. The reaction mixture was shaken at room temperature for 8 hours. The reaction using FITC was shielded from light. Then, the solvent was filtered off and the resin was washed with DCM (3×5 mL) and DMF (3×5 mL). R'-OSu included biotin-OSu (0.2 mmol, 68 mg), MCA-OSu (0.2 mmol, 66 mg) and FAM-OSu (0.2 mmol, 95 mg).
Synthesis of TL1 and TL2 using Fmoc-Lys(MPEG6CH2CO)-OH or Fmoc-Lys(MPEG6(CH2)5CO)-OH
Fmoc-Lys(MPEG6(CH2)nCO): To a solution of MPEG6CH2COOH (5 mmol, 1.8 g) or MPEG6(CH2)5COOH (5 mol, 2.1 g) in DCM (10 ml), HOSu (6 mmol, 0.7 g) and EDC·HCl (6 mmol, 1.2 g) was added. The reaction mixture was stirred at room temperature for 4 hours. Then, the solution was washed with 5% HCl solution (5 mL), water (5 mL), 5% NaHCO3 solution (5 mL) and water (5 mL). The organic layer was dried over anhydrous Na2SO4 and filtered, then the filtrate was concentrated under vacuum to afford active ester. To a solution of Fmoc-Lys-OH·HCl (5 mol, 2.0 g) in carbonate buffer (pH 9, 20 mL), the active ester was added. The reaction mixture was stirred at room temperature for 1 hours. Then, the aqueous solution was extracted with DCM (3×5 mL). The combined organic layer was dried over anhydrous Na2SO4 and filtered, then the filtrate was concentrated under vacuum to afford Fmoc-Lys(MPEG6CH2CO)-OH (2.4 g, yield 69%) or Fmoc-Lys(MPEG6(CH2)5CO)-OH (2.8 g, yield 74%).
TL1 and TL2 ： Peptide was synthesized by SPPS using Fmoc/t-Bu strategy on 100 mg of Fmoc-Tyr(t-Bu)-Resin (0.05 mmol, 0.52 mmol/g). The resin was suspended in 20% piperidine in DMF (v/v, 5 mL) for 30 minutes. The solvent was filtered off and the resin was washed with DMF (3×5 mL). For the attachment of the second amino acid, Fmoc-Val-OH (0.2 mmol, 68 mg) was anchored to the resin using EDC·HCl (0.2 mmol, 38 mg) and HOBt (0.2 mmol, 27 mg) in DMF (4 mL) for 2 hours. A negative ninhydrin test (colorless) indicated that the reaction was complete. After removal of the Fmoc group, the other Fmoc-protected amino acid derivatives were anchored to the resin in the following sequence After attachment of Fmoc-Arg(Pbf)-OH, the resin was suspended in 20% piperidine in DMF (v/v, 5 mL) for 30 minutes. The solvent was filtered off and the resin was washed with DMF (3×5 mL). The resin was shrunk with MeOH (2×5 mL). The peptide was cleaved from the resin with 50% TFA in DCM (v/v, 5 mL) for 2 hours. The reaction mixture was filtered and the filtrate was concentrated under vacuum. The residue was dissolved in water, then freeze-dried to give the solid (TL1: 42 mg, purity 46%; TL2: 39 mg, purity 62%). The HPLC yield of TL1 and TL2 was 37% and 43% respectively.
Analysis and identification of thymopentin derivatives
The desired modified peptides were analyzed by analytical RP-HPLC (SinoChrom ODS-BP column (4.6 mm×250 mm, 5 μm); 0.1% TFA in H2O and 0.1% TFA in CH3CN (5%-95%, 60 minutes); 1 mL·min -1 ; 220 nm) and HR-ESI-MS analysis was employed to confirm the identity of the peptides. The HPLC yields were calculated according to the HPLC purities and the mass of the crude peptides. Finally, the crude product was purified by preparative RP-HPLC (SinoChrom ODS-BP column (20 mm×250 mm, 5 μm); 0.1% TFA in H2O and 0.1% TFA in CH3CN (5%-95%, 60 minutes); 16 mL·min -1 ; 220 nm). The analytical data of thymopentin derivatives were shown in Table S1 . 
